O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results
B. Monk, T. Van Gorp, D. Lorusso, R. Eilish O’Cearbhaill, A. Westermann, Sri Banerjee, D. Collins, J. Klat, K. Madsen, J. Baurain, A. Jackson, I. Boere, S. Pignata, E. Gort, J. Moroney, I. Soumaoro, CM Andreassen, L. Nicacio, C. Gennigens, I. Vergote
{"title":"O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results","authors":"B. Monk, T. Van Gorp, D. Lorusso, R. Eilish O’Cearbhaill, A. Westermann, Sri Banerjee, D. Collins, J. Klat, K. Madsen, J. Baurain, A. Jackson, I. Boere, S. Pignata, E. Gort, J. Moroney, I. Soumaoro, CM Andreassen, L. Nicacio, C. Gennigens, I. Vergote","doi":"10.1136/ijgc-2021-igcs.13","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19692,"journal":{"name":"Oral abstracts","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
